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ABSTRACT: Drug resistance has been reported for every antimalarial in use highlighting
the need for new strategies to protect the eﬃcacy of therapeutics in development. We have
previously shown that resistance can be suppressed with a population biology trap: by
identifying situations where resistance to one compound confers hypersensitivity to
another (collateral sensitivity), we can design combination therapies that not only kill the
parasite but also guide its evolution away from resistance. We applied this concept to the
Plasmodium falciparum dihydroorotate dehydrogenase (PfDHODH) enzyme, a well
validated antimalarial target with inhibitors in the development pipeline. Here, we report a
high-throughput screen to identify compounds speciﬁcally active against PfDHODH
resistant mutants. We additionally perform extensive cross-resistance proﬁling allowing us
to identify compound pairs demonstrating the potential for mutually incompatible
resistance. These combinations represent promising starting points for exploiting collateral
sensitivity to extend the useful lifespan of new antimalarial therapeutics.
KEYWORDS: DHODH, malaria, collateral sensitivity, drug resistance, drug combinations
Over the last 15 years, renewed eﬀorts to control malariadisease and transmission have led to a 37% reduction in
incidence and a 60% reduction in mortality worldwide.1
Eﬀective treatment is a cornerstone of malaria eradication
eﬀorts. However, the emergence of drug resistance threatens
these fragile gains. Resistance has been reported for every
antimalarial that has been in clinical use,2 and there is an urgent
need to develop not only new antimalarial drugs but also
strategies to combat resistance and prolong the useful lifespan
of these therapies.
The problem of resistance is not limited to antimalarial drugs
but is a widespread observation in the treatment of all
infectious agents and many cancers.3,4 The strong evolutionary
pressure exerted by drug treatment results in the selection of
resistant organisms or cells. The current strategy to prevent the
emergence of drug resistance is to combine two drugs with
diﬀerent mechanisms of action. Combining therapies with
diﬀerent modes of action can help delay resistance, but this
must be balanced with possible toxic or counterproductive
eﬀects.5 The concept is that resistance is far less likely to
emerge to both of the drugs simultaneously. However, in
practice, there are many examples of this strategy failing in part
because of diﬀerent pharmacological properties of the paired
drugs.6−10
We have previously demonstrated that an alternate approach
based on evolutionary principles could provide a viable path
toward suppressing resistance.11 The underlying hypothesis is
that a mutation that leads to resistance to a particular drug also
has consequences for the ﬁtness of that organism, creating new
vulnerabilities which could potentially be exploited. One such
potential consequence is collateral sensitivity, in which
resistance to one drug causes an increase in sensitivity to
another chemical agent.12 In practical terms, once an enzyme
carries a mutation that confers drug resistance, that enzyme has
increased sensitivity to other small molecules that preferentially
recognize the altered or mutant form. The concept is then to
combine a wild-type speciﬁc drug with a mutant speciﬁc drug in
order to block resistance from emerging. We found two such
instances in our original work: a molecule that was speciﬁc for
chloroquine-resistant parasites and was inactive against sensitive
parasites.13 A second combination targeted dihydroorotate
dehydrogenase (DHODH), one of the newly identiﬁed targets
for antimalarial drug development.11,13 Subsequently, other
examples have been published including inhibitors of
PfATPase4,14 antibacterials,15,16 and cancer therapeutics.17,18
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The purpose of the work described here was to further
investigate the strategy of designing drug combinations based
on collateral evolutionary forces. We focused on the enzyme
DHODH in part because we had demonstrated the feasibility of
this approach previously and because it is one of the drug
targets currently being targeted for development under MMV
sponsorship. The goal was to identify potential compounds that
could be combined to target DHODH wild-type and mutant
forms.
This project is a collaboration between the GlaxoSmithKline
(GSK) Tres Cantos Open Lab and Harvard University and was
conducted at both institutions. We sought to more
comprehensively probe the extent of collateral sensitivity for
the Plasmodium falciparum dihydroorotate dehydrogenase
(PfDHODH) drug target. To do so, we performed a high
throughput screen of wild-type and mutant DHODH enzyme
in order to identify chemotypes that were preferentially active
against resistant forms. Further validation of these molecules
against a larger panel of PfDHODH mutant parasites allowed
us to understand the networks of cross-resistance and collateral
sensitivity for this target and to identify promising compound
combinations designed to suppress the emergence of resistance.
■ RESULTS AND DISCUSSION
To identify PfDHODH inhibitors, and in particular com-
pounds active against the mutant form of the enzyme, we
performed a high throughput screen (HTS) of select GSK
chemical libraries. We screened the E182D mutant enzyme as it
had independently arisen in selections using diverse chemical
scaﬀolds, and our previous studies suggested it could represent
an optimal ﬁtness-resistance compromise for the enzyme.13 To
screen the mutant and wild-type enzymes, we utilized a
previously optimized in vitro colorimetric assay that measures
enzyme activity by coupling the oxidation of the dihydroorotate
(DHO) substrate with the reduction of 2,6-dichloroindophenol
(DCIP).19,20 The mutant (E182D) enzyme was recombinantly
expressed and tested against select libraries at GSK, amounting
to a total of 130 887 small molecules assessed. Data for the
inhibition of the wild-type (WT) enzyme was previously
obtained by GSK (1.1% hit rate, personal communication) and
used as a comparator for the mutant data. Compounds were
ﬁrst tested at a single dose of 5 μM, and hits were deﬁned as
those demonstrating at least 50% inhibitory activity when
compared to vehicle control wells. These 458 hit compounds
(0.35% overall hit rate) were cherry-picked and run in full
dose−response against both the wild-type and mutant enzymes
to determine the half-maximal inhibitory concentration (IC50).
This resulted in 118 primary hits with potent IC50 values.
Comparison of the mutant IC50 relative to wild-type allowed us
to classify compounds as being WT-active (ratio >2), E182D-
active (ratio <0.5), and equally potent (ratio between 0.5 and
2) (Figures 1a and S1, Table S1). Of particular interest for
additional study are the 18 mutant-active and 21 equipotent
molecules as they represent promising starting points to test
our targeting resistance concept.
To further validate their cellular mode of action, we counter-
screened the 118 hit compounds identiﬁed from the enzymatic
screen for activity against the 3D7-WT and 3D7-
DHODH:E182D mutant parasite lines in a whole-cell dose−
response assay. Despite having established inhibitory activity
against the PfDHODH enzyme, it is possible that the cell-based
activity of our compounds could fail to permeate cells or
involve additional pathways other than PfDHODH, thus
confounding our results. To help rule out oﬀ-target activity in
the cell-based assay, we also included a Dd2-ScDHODH
transgenic parasite along with its wild-type parental line, Dd2-
attB, in our secondary screen. The transgenic Dd2-ScDHODH
strain expresses the cytosolic type 1 DHODH from S. cerevisiae
(ScDHODH) and is resistant to P. falciparum electron
transport chain (ETC) inhibitors. Expression of the yeast
enzyme bypasses the parasite’s dependency on ubiquinone for
DHODH activity in the pyrimidine biosynthesis pathway.21
Ablation of compound activity in this cell line relative to its
parent functionally validates its cellular mechanism of action as
inhibition of DHODH or downstream eﬀectors in the ETC.
Compounds were ﬁrst assessed for potency against each of the
four strains. Among the primary hits, 29 compounds showed
poor potency (<40% inhibition at 20 μM) to both 3D7-WT
and 3D7-E182D and were removed from further study. An
additional 12 compounds were discarded as they showed
greater than 40% inhibition against the Dd2-ScDHODH strain
at the lowest dose of 0.2 μM, suggesting oﬀ-target activity
(Table S1).
The remaining 85 compounds (secondary hits) were then
tested in full dose−response (12-point titrations in triplicate),
and 50% eﬀective concentrations (EC50 values) were
determined for both the 3D7-WT and 3D7-DHODH:E182D
Figure 1. Identiﬁcation of 3D7-E182D mutant active, equally potent,
and wild-type active DHODH inhibitors. (a) A high-throughput
screen of select GSK libraries using wild-type and E182D recombinant
PfDHODH identiﬁed 118 primary hits. On the basis of the IC50 ratio
of E182D/WT, compounds were classiﬁed as E182D mutant active (n
= 18), equally potent (n = 21), or wild-type active (n = 69). Control
compounds are indicated on the plot: IDI-6273 (blue), mutant active
control; DSM74 (red), wild-type active control. (b) Cell-based
validation of 85 active compounds. Compounds were classiﬁed into
three groups based on the EC50 ratio of E182D/WT: equally potent (n
= 17), mutant active (n = 7), or wild-type active (n = 59). Control
compounds are indicated on the plot: IDI-6273 (blue), mutant active
control; DSM74 and Genz-669178 (red), wild-type active controls;
dihydroartemisinin (DHA) and meﬂoquine (MQ) (white), non-
DHODH inhibitor controls.
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strains. On the basis of their EC50 ratio (E182D/WT),
compounds were classiﬁed as WT-active (ratio >2), E182D-
active (ratio <0.5), and equally potent (ratio between 0.5 and
2) (Figure 1b). Using these parameters, we identiﬁed 59 WT-
active, 7 E182D-active, and 17 equally potent compounds. On
the basis of overall cellular potency and compound availability,
23 molecules representing ten distinct chemotypes were
selected for further characterization (Figure S2). Of note are
compounds 10 (TCMDC-124417), 9 (TCMDC-124402), 8
(TCMDC-123826), and 15 (TCMDC-125162), which share
structural similarity to the triazolopyrimidine clinical candidate,
DSM265.22,23 We also detected a cluster of molecules
(compounds 2, 4, 6, 7, 11, and 19) with structural similarity
to GSK3, an inhibitor identiﬁed in our previous study as
demonstrating increased potency against mutant parasites.
Figure 2. Extracellular ﬂux analysis conﬁrms the inhibitory activity of compound 21 against both PfCytbc1 and PfDHODH. (a) A schematic
representation of target identiﬁcation using extracellular ﬂux analysis. When G3P is provided as a fuel source, Cytbc1 inhibitors such as antimycin A
and compound 21 disrupt the electron ﬂow of the ETC resulting in a reduction in the OCR. When DHO is the only fuel source provided, thus
activating DHODH, electron ﬂow and the OCR are reduced by DHODH inhibitors, such as Genz669178 and compounds 1 and 21. (b) Structures
of compounds tested in the extracellular ﬂux assay. Genz669178 is a control DHODH inhibitor and antimycin A is a control Cytbc1 inhibitor. (c)
Antimycin A and compound 21 decreased OCR in RPMI media, indicating Cytb inhibition. Compound 1 and the DHODH inhibitor control
Genz669178 do not have an eﬀect on the OCR, similar to media-only controls. All data represent means ± SD (n = 3). (d) Compound 1, compound
21, and Genz669178 reduced the DHO-induced OCR, indicating their DHODH activity, while the Cytb inhibitor, antimycin A, did not. All data
represent means ± SD (n = 3). (e) As observed in RPMI media conditions, only compound 21 and antimycin A reduced the OCR when G3P was
the sole substrate. All data represent means ± SD (n = 3).
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An inhibitor with dual P. falciparum Cytochrome b (PfCytb)
and PfDHODH activities was recently reported,24 prompting
us to assess whether some of our hits also demonstrate the
ability to inhibit both enzymes. A compound with dual activity
could be incorrectly scored as a PfDHODH mutant selective
compound due to the confounding eﬀects of its PfCytb activity.
To test this and rule out any such false-positives in our data set,
we assayed our set of 23 secondary hits in the Dd2-ScDHODH
parasite line in both the presence and absence of 1 μM
proguanil (Table S2). The small molecule proguanil works
synergistically with Cytochrome b (Cytb) inhibitors in
P. falciparum and can rescue the apparent resistance observed
in the ScDHODH parasite line.21,24 In contrast, proguanil has
no eﬀect on the activity of PfDHODH inhibitors when added
to assay conditions.24,25 As summarized in Table S2, all tested
compounds were at least 10-fold less active against Dd2-
ScDHODH compared to the parental Dd2-attB, and the
addition of proguanil largely had no eﬀect on EC50. This is
comparable to the control PfDHODH inhibitor, Genz669178.
However, proguanil dramatically improved the cell-based
activity of compound 21 (TCMDC-136129) similar to the
eﬀect seen for the control PfCytb inhibitor atovaquone. On the
basis of these results, we hypothesize that 21 targets both
PfDHODH and PfCytb.
To further validate the dual cellular activity of 21, we utilized
extracellular ﬂux analysis to directly test the ability of the
molecule to inhibit speciﬁc steps of the electron transport chain
in cells. Using methodology developed in our group, the
oxygen consumption rate (OCR) of saponin-freed schizonts
can be directly measured as an output of Complexes I−IV of
the electron transport chain.26 Inhibitors of any of the enzymes
along the chain result in a reduction of OCR; by varying the
input energy source provided to the cells, the system allows for
the functional identiﬁcation of the speciﬁc target of the
compound.26 When schizonts were assayed in RPMI medium,
which contains fuel molecules such as glucose and glutamine,
all dehydrogenases function normally and provide electrons to
the downstream Cytbc1 complex (Complex III). Inhibition of
Cytbc1 results in a reduction of the OCR (Figure 2c). However,
in these media conditions, DHODH inhibition does not
signiﬁcantly alter the OCR, presumably because electron ﬂow
from other dehydrogenases mask the eﬀect of DHODH
inhibition. As shown in Figure 2c, Genz669178 and compound
1 (N16306-26-3), inhibitors that only target PfDHODH, had
no eﬀect on the OCR, while 21 and the control Cytb inhibitor
antimycin A were able to dramatically decrease OCR, exhibiting
their direct inhibition of Cytb. This ﬁnding was further
demonstrated in minimal media assay conditions when the
only fuel source provided was glycerol 3-phosphate (G3P)
(Figure 2e). In contrast, when the assay is conducted in
minimal media conditions in which DHO is the only substrate
provided (and only DHODH is activated), OCR reduction by
DHODH inhibitors can be observed. As expected, 21, 1, and
the control Genz669178 decreased OCR after DHO was added
to schizonts (Figure 2d).
We additionally tested the direct inhibition of the PfCytbc1
complex using an in vitro enzymatic assay. Mitochondria were
isolated from saponin-released parasites and cytochrome c
reductase activity was measured by the method of Fry and
Pudney.27 Addition of compound 21 reduced enzymatic
activity in a dose-dependent manner resulting in an IC50 of
40 nM (Table S3). The PfDHODH speciﬁc inhibitor, DSM1,
did not have an eﬀect on activity. Taken together, these results
provide evidence supporting our hypothesis that 21 directly
inhibits both PfDHODH and Complex III.
The overall aim of our study was to identify inhibitors that
target mutant forms of the PfDHODH enzyme. To extend the
ﬁndings of our screening eﬀorts, which focused on the E182D
mutant, we assayed 17 of our cherry-picked compounds against
a broader panel of ﬁve DHODH mutant parasite lines. These
parasites were generated from in vitro selections with DHODH
inhibitors of varying chemical classes (Table S4).11,13 All
resistant cell lines have point mutations in the PfDHODH locus
resulting in amino acid changes in residues lining the inhibitor
binding pocket of the enzyme (Figure 3a).
We determined EC50 values for each compound assayed
against the ﬁve DHODH mutants, as well as their 3D7 and Dd2
parental lines (Table S5). The compounds all demonstrate
activity against the wild-type parents (EC50 range from 1.8 to
600 nM) and show decreased activity (cross-resistance), equal
potency, or increased activity (collateral sensitivity) in the
mutant cell lines (Table S5). To further explore patterns of
cross-resistance and collateral sensitivity, the EC50 fold-change
for each mutant relative to its parental line was calculated and
then the log10-transformed values were visualized on a heatmap.
This visualization showed that certain mutants have very similar
cross-resistance proﬁles (e.g., I263F and E182D or F227I and
the double mutant F227I/L527I) while the L531F mutant had
a unique phenotypic proﬁle. On the basis of this clustering, we
tested an additional set of six secondary hits using only the
I263F, F227I, and L531F mutants, as compound availability
was limited (Figure 3b). Overall, we observed both patterns of
cross-resistance (shades of red) and collateral sensitivity
(shades of blue) in our data set (Figure 3b). For example,
compounds 10, 9, 8, and 15, which are structurally related to
DSM265 (see Figure S2), demonstrate signiﬁcant cross-
resistance in all of the cell lines tested. In contrast, we observe
collateral sensitivity to compounds 17 (TCMDC-125334) and
16 (TCMDC-125331). Compound 22 (TCMDC-136379) was
also of note as it demonstrated potency against the I263F
mutant. This mutant was the most “pan-resistant” showing
cross-resistance to most chemotypes.
Of particular interest were compounds with complementary
activities across our panel of mutant parasite lines (Figure 4a).
As noted above, all of the mutants tested demonstrated cross-
resistance against compounds with a triazolopyrimidine
scaﬀold, whereas they were sensitive to compound 17. Given
these opposing phenotypic proﬁles, we hypothesize that a
combination of 17 and 8 could provide a basis for suppression
of resistance studies. Another example is the pairing of
compound 6 (TCMDC-123647) and 7 (TCMDC-123823).
Compound 6 is active against the E182D and I263F mutants
and relatively inactive against the L531F, F227I, and F227I/
L527I mutant cell lines whereas compound 7 has the opposite
activity proﬁle: highly potent against L531F, F227I, and F227I/
L527I while relatively inactive against E182D and I263F
(Figure 4b). The compounds 1 and 5 (TCMDC-123620)
display a similar activity proﬁle (Figure 4c). Further resistance
studies are needed to test the hypothesis that any of these
compound pairings could result in the suppression of
resistance.
In this work, we took a unique HTS approach aimed at
identifying small molecules that speciﬁcally target mutant forms
of PfDHODH. Our primary screen identiﬁed 118 molecules
with activity against either wild-type and/or mutant
PfDHODH. Validation of these primary hits in cell-based
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assays resulted in the classiﬁcation of 7 mutant active, 17
equally active, and 59 wild-type active small molecules.
Extensive cross-resistance proﬁling of 23 cherry-pick com-
pounds against a broad panel of PfDHODH mutant cell lines
illuminated patterns of cross-resistance and collateral sensitivity.
The molecules demonstrating collateral sensitivity against all or
a subset of mutants represent promising starting points for
further suppression of resistance studies. It is important to note
that while we have observed strong correlation between mutant
enzyme activity and mutant cell line activity in previous
studies,11 we cannot rule out oﬀ-target eﬀects in using a cell-
based assay with the compounds explored in this study. Future
eﬀorts to evaluate this would be valuable.
Over the course of these eﬀorts, we also discovered and
validated a compound that targets both PfDHODH and
PfCytb in the parasite. This presents an interesting possibility
for what eﬀectively amounts to combination treatment through
a single molecule. However, questions remain as to how easily
the parasite can evolve resistance to this dual-inhibitor through
mutations in either target, rendering the molecule ineﬀective.
Because there is not an evolutionary constraint preventing the
parasite from mutational escape in either enzyme, we suspect
that resistance to this inhibitor could arise relatively easily
despite its ability to inhibit two enzymes in the parasite.
The challenge of drug resistance is often presented as a
never-ending arms race between our ability to reﬁll an arsenal
with new drugs and the ability of a pathogen to evolve
resistance. Our eﬀorts focus on targeting the evolutionary
changes that lead to resistance in the ﬁrst place; we seek not
only to reﬁll the arsenal but also to develop ways in which we
can exploit the ﬁtness costs associated with resistance in order
to trap the parasite in an evolutionary loop that favors a drug-
sensitive population. Comprehensively exploring the relation-
ships of cross-resistance and collateral sensitivity in a panel of
PfDHODH mutants allowed us to develop a network of
collateral sensitivity for this target and identify pairs of
compounds demonstrating the potential for mutually incom-
patible resistance. Notably, we were able to identify
complementary pairs of compounds that together targeted all
of the resistance mutations tested in this study, suggesting that
this may be a feasible strategy to close oﬀ potential pathways to
resistance. Studies to fully explore resistance to each of these
molecules individually and in combination are warranted. It will
also be critical to determine whether particular resistance
pathways are favored in vivo and match those from our in vitro
studies. Future eﬀorts aim to explore this and prioritize
compounds that speciﬁcally block these in vivo-relevant
mutants.
■ METHODS
Reagents. L-Dihydroorotic acid (DHO), CoQD, DCIP,
antimycin A, atovaquone (ATV), meﬂoquine (MQ), artemisi-
nin, dihydroartemisinin (DHA), and proguanil were purchased
from Sigma-Aldrich (St. Louis, MO). Genz-669178, was kindly
provided by Genzyme, a Sanoﬁ Company (Waltham, MA).
IDI-6273 was purchased from ChemDiv. DSM1 and DSM74
were prepared following the literature procedure28 and were
recrystallized from ethanol. 1H NMR spectra matched that
reported, and HPLC analysis indicated >95% purity.
In Vitro Enzyme Activity Assay for HTS. Recombinant
wild-type and E182D protein were expressed in E. coli and
puriﬁed as previously described.11 Enzyme activity was
measured using published protocols19,20 with slight modiﬁca-
tions to the reaction conditions as follows: 500 μM DHO, 60
μM DCIP, 100 μm CoQD, and 0.125% Triton X-100 in a 50 μL
reaction volume in 384-well plates. The absorbance at 600 nm
was read every 5 min for 30 min, and the slopes of the lines
were used to determine inhibition. HTS quality was assessed by
Z-factor, with an overall value of ∼0.7.
Figure 3. Cross-resistance proﬁling of multiple selected parasite lines
reveals patterns of collateral sensitivity. (a) Structure of PfDHODH
displaying the resistance mutations in the parasite lines proﬁled in this
study (see Table S3). The image was generated in CCP4 mg33 using
coordinates from the crystal structure of PfDHODH bound to the
Genz669178 inhibitor, PDB ID: 3o8a.11 (b) Heatmap based on fold-
change in EC50 of each compound across every resistant cell line
tested. Both cell lines and compounds are clustered on the basis of
log10-transformed activity proﬁles. Shades of red indicate cross-
resistance, while shades of blue indicate collateral sensitivity. White
and light shades indicate no signiﬁcant fold-change between mutant
and wild-type lines. Gray boxes indicate that the compound was not
tested against the given mutant line due to limited compound
availability.
ACS Infectious Diseases Letter
DOI: 10.1021/acsinfecdis.7b00217
ACS Infect. Dis. 2018, 4, 508−515
512
Parasite Culture. The erythrocytic stages of all P. falciparum
strains used in this study were cultured by standard methods29
in solutions of 5% human O+ hematocrit in RPMI 1640
medium (Life Technologies) supplemented with 28 mM
NaHCO3, 25 mM HEPES, 0.5% (w/v) AlbuMAX II (Life
Technologies), 50 mg/mL hypoxanthine, and 25 μg/mL
gentamycin. Human blood was supplied from Interstate
Blood Bank. The human biological samples were sourced
ethically, and their research use was in accord with the terms of
the informed consents. Cultures were maintained at 37 °C in a
gas mixture of 1.1% O2, 4% CO2, and 95% N2 and regularly
synchronized by 5% sorbitol treatment.30
Parasite Strains. Laboratory reference strains used were the
3D7 (MRA-151) and a Dd2 clone derived from MR4 line
MRA-156 (MR4, BEI Resources). Parasite lines with point
mutations in PfDHODH were generated via in vitro resistance
selections as described11,13 (Table S3). The Dd2-ScDHODH
transgenic line expressing the Saccharomyces cerevisiae DHODH
was a gift from Jeﬀ Dvorin.31
Whole-Cell Dose−Response Assay and EC50 Determi-
nation. Drug susceptibility was measured by a growth assay as
previously reported.19,20 To initially verify cell-based activity of
the primary HTS hits, three doses (0.2, 2.0, 20 μM) were tested
in duplicate. Compounds with at least 40% inhibitory activity at
the 2 μM dose were then tested in full 12-point dose−response
in a 72 h assay with a SYBR-green readout. EC50 values were
calculated using a nonlinear regression curve ﬁt in Prism
Software version 7 (GraphPad).
Analysis of Cross-Resistance Proﬁling. The extent of
cross-resistance or collateral sensitivity was determined by
dividing the EC50 of a given mutant line by the EC50 of the
parent reference strain and taking the log10 of this EC50 ratio.
These values were visualized on a heatmap generated by
MultiExperimentViewer (MeV) version 4.9.0 with hierarchical
clustering based on Euclidean Distance using average linkage.32
Figure 4. Activity proﬁles of compound pairs exhibiting mutually incompatible resistance. Scatter plots display the EC50 values of the indicated
compound for each of the selected parasite lines tested. The parental lines 3D7 (closed circle) and Dd2 (closed square) are in black, while the
mutant cell lines are indicated in blue and red to represent distinctive cross-resistance phenotypes (E182D, red closed circle; I263F, red closed
square; L531F, blue ×; F227I, open blue circle; F227I/L527I, open blue circle with ×). (a) Structures of compound pairs highlighted by our analysis.
(b) Compound 8 is a wild-type active compound which is relatively inactive against all mutant lines tested. In contrast, compound 17 is an example
of a mutant-active compound, as all mutant lines tested are more sensitive than the parental lines. These two compounds could be paired together as
a strategy to target resistance. (c) Compound 7 targets the L531F, F227I, and F227I/L527I mutants, while compound 6 targets E182D and I263F.
(d) An additional example of a compound pair with complementary activities. Compound 1 targets the L531F, F227I, and F227I/L527I mutants,
while compound 5 targets E182D and I263F.
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In cases where the EC50 value was outside the range of the
highest dose tested, the minimum estimate as listed in Table S4
was used as a placeholder value to generate the heatmap.
Extracellular Flux Analysis Using XFe24 Analyzer.
Extracellular ﬂux analysis was conducted as previously
reported26 using either unbuﬀered RPMI medium or
mitochondria assay solution (MAS). MAS was composed of
mannitol (220 mM), sucrose (70 mM), KH2PO4 (10 mM),
MgCl2 (5 mM), HEPES (2 mM), EGTA (1 mM), and fatty
acid free BSA (0.2% w/v). Both media were adjusted to pH 7.4,
and digitonin (2 μM) was added freshly on the day of the assay.
Schizonts were freed from red blood cells (RBCs) by 0.01%
saponin and seeded in an XF24-well microplate with wells
pretreated with CellTak cell and tissue adhesive (Fisher
Scientiﬁc, CB-40241) at 11 million cells/well. Test compounds
and DHO were injected at prescheduled timing as 10× in the
corresponding assay medium, and measurements were
performed with the following setting: mix time, 30 s; wait
time, 1 min 30 s; measure time, 3 min.
Isolation of Parasite Mitochondria and Cytochrome c
Reductase Activity Assay. Mitochondria were isolated and
cytochrome c reductase activity was measured using a
modiﬁcation of the method developed by Fry and Pudney27
as previously described.31 In brief, saponin-released parasites
were lysed by N2 cavitation, and the clariﬁed lysate was further
enriched for mitochondria by centrifugation and separation on
a sucrose gradient. Isolated mitochondria were washed of
sucrose and stored at −80 °C until the time of the assay.
Cytochrome c reductase activity was measured as follows:
mitochondria (40 μg/mL) were diluted in reaction buﬀer (250
mM sucrose, 50 mM KH2PO4, 0.2 mM EDTA, 1 mM NaN3,
and 2.5 mM KCN) containing 50 μM cytochrome c. Reactions
were started by addition of 25 μM decylubiquinol and
monitored by reduction of cytochrome c at 550 nm. To ensure
the linearity of the enzymatic reaction, only data from the ﬁrst
60 s were collected.
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